Skip to contentSkip to main content

Vitamin B2 and riboflavin-5-phosphate · Evidence and safety guide

Riboflavin (vitamin B2): migraine dose, benefits, forms and safety

Riboflavin is essential vitamin B2.

Food reliably prevents deficiency, and clinician-led replacement corrects it. For adult migraine prevention, 400 mg/day for about three months has a meaningful signal, but trials are small and highly heterogeneous; it is not an established acute treatment. Children have mixed evidence. Riboflavin-5-phosphate sounds ‘active’, but no adequate head-to-head clinical trial shows better migraine or health outcomes than ordinary riboflavin.1,3,4,5,6,7,8,9,14,15

Strong
Updated August 10, 202635 min readHuman evidence first
White riboflavin tablet beside pale yellow crystalline vitamin B2 powder and a luminous flavin-inspired molecular ribbon on cream and deep navy surfaces

At a glance

Riboflavin

Overall evidence
Strong for adequacy and deficiency; moderate but heterogeneous for adult migraine prevention1,4,5,6,7StrongFinding: mixed results
US adult requirement
1.3 mg/day for men and 1.1 mg/day for women1,2StrongFinding: established use
Adult migraine studies
Most commonly 400 mg/day for three months; preventive, not acute3,4,5,6,7,34ModerateFinding: benefit supported
Best-known adult trial
59% versus 15% achieved at least 50% fewer headache days; only 55 adults5ModerateFinding: benefit supported
Single-dose absorption
A small study estimated a maximum absorbed amount near 27 mg; this is not an outcome ceiling14ModerateFinding: established use
Best-supported form
Ordinary riboflavin; R5P has no proven outcome advantage1,5,14,15StrongFinding: mixed results
Upper limit
None established because evidence is insufficient—not because every dose is proven safe1,18,19StrongFinding: established use
Reassess
Three months for migraine; earlier for adverse effects, pregnancy or clinical changes3,5,24ModerateFinding: established use

Study findings describe groups, not a guaranteed result for one person.

Research and writing

LongevityMate Editorial Team

Editorial oversight

Lukas Dvorsky, Founder

Clinical review

Not yet assigned or claimed